The complexity of interactions in the tumor microenvironment, arginase inhibition in different cells and anti-PD-1 inhibition resulting in changes of the immune compartment may explain a low number of differentially expressed genes in the COMB group and a small overlap of OAT-1746 mono and combined treatment Future testing of the drug efficacy on established tumors, alternatively to the currently studied preventive treatment regimen, would provide additional information on a mode of action and a translational potential of OAT-1746. This evidence concerns the gene PDCD1 and neoplasm.